United States-based Senores Pharmaceuticals, Inc announced on Monday that it has launched its Nicardipine Hydrochloride Capsules USP, 20mg and 30mg, a bioequivalent and therapeutically equivalent to Chiesi USA's Cardene Capsules, 20mg and 30mg, in the United States.
Burel Pharmaceuticals, LLC is to market the product.
The product is indicated for the management of patienrs with chronic stable angina (effort-associated angina) and for the treatment of hypertension.
The company has received a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP, 20mg and 30mg. With this approval, the company is eligible for 180 days of CGT exclusivity upon commercial marketing.
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia